Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women

Clinical Infectious Diseases

Volumn 56, Issue 12, 2013, Pages 1704-1712

  Khamduang, Woottichai ^a,b,c   Ngo Giang Huong, Nicole ^a,b,d   Gaudy Graffin, Catherine ^c   Jourdain, Gonzague ^a,b,d   Suwankornsakul, Weerapong ^e   Jarupanich, Tapnarong ^f   Chalermpolprapa, Veeradate ^g   Nanta, Sirisak ^h   Puarattana Aroonkorn, Noossara ⁱ   Tonmat, Sakchai ^j   Lallemant, Marc ^a,b,d   Goudeau, Alain ^c   Sirirungsi, Wasna ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Institute of research for development Thailand   (Thailand)

^c UNIVERSITÉ DE TOURS   (France)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e Rayong Hospital   (Thailand)

^f Hat Yai Hospital   (Thailand)

^g Nakhonpathom Hospital   (Thailand)

^h Thailand MOPH   (Thailand)

ⁱ Nongkhai Hospital   (Thailand)

^j Mahasarakam Hospital   (Thailand)

more..

Author keywords

HIV 1 infected pregnant women; isolated anti HBc; occult HBV infection; perinatal transmission

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS C ANTIBODY; NEVIRAPINE; VIRUS DNA; ZIDOVUDINE;

ADULT; ANTIBODY DETECTION; ARTICLE; BIRTH; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; DNA DETERMINATION; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANCY; INFANT; MAJOR CLINICAL STUDY; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SINGLE DRUG DOSE; THAILAND; VERTICAL TRANSMISSION;

HIV-1-INFECTED PREGNANT WOMEN; ISOLATED ANTI-HBC; OCCULT HBV INFECTION; PERINATAL TRANSMISSION;

ADULT; ANALYSIS OF VARIANCE; COHORT STUDIES; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; RISK FACTORS; THAILAND; VIRAL LOAD;

EID: 84878320341     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit166     Document Type: Article

References (40)

1. Grob P, Jilg W, Bornhak H, et al. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 2000; 62:450-5.
2. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978; 298:1379-83.
3. De Feo TM, Poli F, Mozzi F, Moretti MP, Scalamogna M. Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transplant Proc 2005; 37:1238-9.
4. Descos B, Scotto J, Fayol V, et al. Anti-HBc screening for the prevention of perinatal transmission of hepatitis B virus in France. Infection 1987; 15:434-9.
5. Chamorro AJ, Casado JL, Bellido D, Moreno S. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker. Eur J Clin Microbiol Infect Dis 2005; 24:492-4.
6. Jain M, Chakravarti A, Kar P. Clinical significance of isolated anti-HBc positivity in cases of chronic liver disease in New Delhi, India. J Glob Infect Dis 2009; 1:29-32.
7. Ikeda K, Kobayashi M, Someya T, et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 2009; 16:437-43.
8. Sheng WH, Kao JH, Chen PJ, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 45:1221-9.
9. Hoffmann CJ, Seaberg EC, Young S, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23:1881-9.
10. Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood 2002; 100:2637-41.
11. Asim M, Ali R, Khan LA, Husain SA, Singla R, Kar P. Significance of anti-HBc screening of blood donors and its association with occult hepatitis B virus infection: implications for blood transfusion. Indian J Med Res 2010; 132:312-7.
12. Thedja MD, Roni M, Harahap AR, Siregar NC, Ie SI, Muljono DH. Occult hepatitis B in blood donors in Indonesia: altered antigenicity of the hepatitis B virus surface protein. Hepatol Int 2010; 4:608-14.
13. Seo DH, Whang DH, Song EY, Kim HS, Park Q. Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infections in Korean blood donors. Transfusion 2011; 51:1840-6.
14. Gandhi RT, Wurcel A, Lee H, et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 2003; 36:1602-5.
15. Neau D, Winnock M, Galperine T, et al. Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. HIV Med 2004; 5:171-3.
16. Liang SH, Chen TJ, Lee SS, et al. Risk factors of isolated antibody against core antigen of hepatitis B virus: association with HIV infection and age but not hepatitis C virus infection. J Acquir Immune Defic Syndr2010; 54:122-8.
17. Gandhi RT, Wurcel A, McGovern B, et al. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr 2003; 34:439-41.
18. French AL, Operskalski E, Peters M, et al. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis 2007; 195:1437-42.
19. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimon-do G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341:22-6.
20. Jongjirawisan Y, Ungulkraiwit P, Sungkanuparph S. Isolated antibody to hepatitis B core antigen in HIV-1 infected patients and a pilot study of vaccination to determine the anamnestic response. J Med Assoc Thai 2006; 89:2028-34.
21. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004; 86:83-91.
22. Sun HY, Lee HC, Liu CE, et al. Factors associated with isolated antihepatitis B core antibody in HIV-positive patients: impact of compromised immunity. J Viral Hepat 2010; 17:578-87.
23. Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006; 20:1253-60.
24. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevi-rapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-28.
25. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39:1085-9.
26. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207; quiz CE201-204.
27. Laukamm-Josten U, Muller O, Bienzle U, Feldmeier H, Uy A, Guggen-moos-Holzmann I. Decline of naturally acquired antibodies to hepatitis B surface antigen in HIV-1 infected homosexual men. AIDS 1988; 2:400-1.
28. Manzini P, Girotto M, Borsotti R, et al. Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica 2007; 92:1664-70.
29. Ponde RA, Cardoso DD, Ferro MO. The underlying mechanisms for the 'anti-HBc alone' serological profile. Arch Virol 2010; 155: 149-58.
30. Poovorawan Y, Theamboonlers A, Vimolket T, et al. Impact of hepatitis B immunisation as part of the EPI. Vaccine 2000; 19:943-9.
31. Louisirirotchanakul S, Myint KS, Srimee B, et al. The prevalence of viral hepatitis among the Hmong people of northern Thailand. Southeast Asian J Trop Med Public Health 2002; 33:837-44.
32. Pradutkanchana S, Nasongkla K, Pradutkanchana J, Heembai U. A ten-year trend of the prevalence of hepatitis B surface antigen in pregnant women at Songklanagarind hospital. J Infect Dis Antimicrob Agents 2005; 22:111-4.
33. Berger A, Doerr HW, Rabenau HF, Weber B. High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen. Intervirology 2000; 43:71-6.
34. Chen SY, Kao CF, Chen CM, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 2003; 278:591-607.
35. Schuttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002; 37:855-62.
36. Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol 2004; 11:18-25.
37. Lo Re V 3rd, Frank I, Gross R, et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44:315-20.
38. Walz A, Wirth S, Hucke J, Gerner P. Vertical transmission of hepatitis B virus (HBV) from mothers negative for HBV surface antigen and positive for antibody to HBV core antigen. J Infect Dis 2009; 200: 1227-31.
39. Soderstrom A, Norkrans G, Lindh M. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis 2003; 35:814-9.
40. Wang JS, Chen H, Zhu QR. Transformation of hepatitis B serologic markers in babies born to hepatitis B surface antigen positive mothers. World J Gastroenterol 2005; 11:3582-5.